Aetna modified CPB 0964 for crizanlizumab-tmca (Adakveo), effective December 10, 2025. Here's what changes for billing teams.
Aetna, a CVS Health company, updated its crizanlizumab-tmca (Adakveo) coverage policy under CPB 0964 in Aetna's commercial medical plan system. This policy governs HCPCS code J0791 and CPT code 96365 for sickle cell disease patients who require IV infusion therapy to reduce vaso-occlusive crises. If your practice bills J0791 for Adakveo infusions, review the updated criteria before the December 10, 2025 effective date.
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Crizanlizumab-tmca (Adakveo) — CPB 0964 |
| Policy Code | CPB 0964 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology, Sickle Cell Disease specialists, Infusion centers |
| Key Action | Audit your J0791 claims to confirm patients meet genotype-specific criteria before submitting precertification requests after December 10, 2025 |
Aetna Crizanlizumab-tmca (Adakveo) Coverage Criteria and Medical Necessity Requirements 2025
The Aetna crizanlizumab-tmca coverage policy under CPB 0964 in the Aetna system is more specific than many drug policies you'll encounter. It splits patients into two distinct tracks based on genotype, and each track carries different medical necessity requirements. Getting this wrong means a claim denial — and these are expensive drugs.
Prescriber Requirement
First, a hematologist or a sickle cell disease specialist must prescribe Adakveo. A primary care physician writing this script alone won't satisfy the criteria. If your practice sees referrals from outside hematology, flag this before you even start the prior authorization process.
Age and VOC History
The member must be 16 years of age or older. They must also have experienced at least one vaso-occlusive crisis (VOC) within the previous 12 months. Document this VOC in the chart with dates. Aetna will ask for it during precertification, and missing documentation is one of the fastest paths to a claim denial.
Genotype Track 1: HbSC, HbSβ+, and Other Variants
Members with sickle hemoglobin C (HbSC), sickle β+-thalassemia (HbSβ+), or other genotypic variants such as HbS-O Arab or HbS-Lepore qualify under Track 1. These members need only satisfy the age and VOC history requirements. There is no hydroxyurea trial requirement for this group. This is a meaningful distinction — don't apply the hydroxyurea criteria to Track 1 patients.
Genotype Track 2: HbSS and HbSβ0
Members with homozygous hemoglobin S (HbSS) or sickle β0-thalassemia (HbSβ0) face an additional hurdle. They must meet at least one of three additional conditions:
| # | Covered Indication |
|---|---|
| 1 | Inadequate response to hydroxyurea, or intolerance to hydroxyurea, at any point in the patient's history |
| 2 | A documented contraindication to hydroxyurea |
| 3 | Concurrent use of hydroxyurea alongside Adakveo |
The "at any time in the past" language on hydroxyurea history is significant. This isn't limited to a recent trial. A patient who tried hydroxyurea years ago and couldn't tolerate it qualifies. Pull that history and document it explicitly in your precertification paperwork.
Prior Authorization Requirements
Precertification is required for all Aetna participating providers and members on applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 to initiate. Use the Statement of Medical Necessity (SMN) forms available through Aetna's Specialty Pharmacy Precertification portal. There are no exceptions to this requirement — don't bill J0791 without a prior authorization in hand.
Site of Care Policy
Aetna's Site of Care Utilization Management Policy applies to this drug. Adakveo is an IV infusion, and Aetna actively manages where these infusions happen. Reimbursement rates and coverage decisions can vary based on whether the infusion occurs in a hospital outpatient setting versus an infusion center or physician office. Check Aetna's Utilization Management Policy on Site of Care for Specialty Drug Infusions before scheduling the first infusion.
Aetna Adakveo Exclusions and Non-Covered Indications
Aetna is direct on this point. Any indication not explicitly listed in the medical necessity criteria is experimental, investigational, or unproven. That's a blanket exclusion covering off-label uses.
The policy does not carve out additional disease states, comorbidities, or combination therapies beyond what's listed. If a physician wants to use Adakveo for a purpose not tied to reducing VOC frequency in sickle cell disease — or for a patient who doesn't meet the genotype and history criteria — expect a denial.
One exception worth noting: the ICD-10 data attached to this policy includes codes for COVID-19 (U07.1), post-COVID-19 condition (U09.9), and pneumonia due to COVID-19 (J12.82). These appear in the code set but are not coverage-qualifying indications under the stated medical necessity criteria. Billing J0791 with a primary COVID-19 diagnosis code will not meet the policy criteria. Those codes likely appear as administrative artifacts in the policy database — don't treat them as evidence of coverage for COVID-related indications.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| VOC reduction in HbSC, HbSβ+, HbS-O Arab, HbS-Lepore — age 16+, ≥1 VOC in past 12 months | Covered | J0791, 96365, D57.00–D57.819 | No hydroxyurea requirement; precertification required |
| VOC reduction in HbSS or HbSβ0 — age 16+, ≥1 VOC, with hydroxyurea failure/intolerance/contraindication or concurrent use | Covered | J0791, 96365, D57.00–D57.819 | Hydroxyurea history or contraindication must be documented; precertification required |
| Continuation of therapy — documented reduction or maintenance of VOC frequency | Covered | J0791, 96365 | Must demonstrate clinical response at renewal |
| All other indications | Not Covered | — | Considered experimental, investigational, or unproven |
| COVID-19, post-COVID-19 condition, COVID-19 pneumonia as primary indication | Not Covered | U07.1, U09.9, J12.82 | Codes present in policy database but not qualifying indications |
Aetna Crizanlizumab-tmca Billing Guidelines and Action Items 2025
Adakveo billing is high-stakes. The drug is expensive, the criteria are narrow, and Aetna requires precertification without exception. Here's what your billing team needs to do.
| # | Action Item |
|---|---|
| 1 | Audit your active J0791 patients against the updated criteria before December 10, 2025. Confirm each patient's genotype is documented (HbSC, HbSβ+, HbSS, HbSβ0, or other variant). Confirm at least one VOC in the past 12 months is in the chart with a date. For HbSS and HbSβ0 patients, confirm hydroxyurea history, contraindication, or concurrent use is documented. |
| 2 | Confirm the prescribing physician is a hematologist or sickle cell disease specialist. If the prescription originates outside that specialty, get a documented consultation before submitting the prior authorization. A note in the chart that a hematologist reviewed the case and agrees with the plan will hold up better than a referral alone. |
| 3 | Submit precertification through Aetna's Specialty Pharmacy Precertification process. Call (866) 752-7021 or fax (888) 267-3277. Use the SMN form. Do this before the infusion is scheduled — not after. Retro-authorization requests for specialty drugs rarely go smoothly. |
| 4 | Verify site of care compliance before scheduling infusions. Aetna's Site of Care policy affects reimbursement and coverage for specialty drug infusions. Confirm the intended infusion site — whether that's a physician office, infusion center, or hospital outpatient department — aligns with Aetna's site of care requirements for this drug. A site-of-care denial is a separate problem from a medical necessity denial, and they require different appeals. |
| 5 | Use the correct ICD-10 code from the D57.00–D57.819 range. This is a range covering sickle-cell disorders. Pick the code that matches the patient's specific genotype and manifestation. Don't use a catch-all code when a more specific one applies — specificity supports medical necessity documentation and reduces audit risk. |
| 6 | Set a renewal trigger for continuation of therapy reviews. Aetna covers continued Adakveo therapy only when the patient has experienced a reduction in VOC frequency — or has maintained that reduction — since starting treatment. Document this at each visit. When authorization renewal approaches, you need clinical evidence of response, not just an ongoing prescription. |
| 7 | Separate COVID-related ICD-10 codes from Adakveo claims. Codes U07.1, U09.9, and J12.82 appear in the policy code set but are not qualifying indications. If a sickle cell patient also has a COVID-related diagnosis, make sure the primary diagnosis driving the J0791 claim is the appropriate D57 code — not a COVID code. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Crizanlizumab-tmca Under CPB 0964
Covered HCPCS and CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0791 | HCPCS | Injection, crizanlizumab-tmca, 5 mg |
| 96365 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| D57.00–D57.819 | Sickle-cell disorders (full range) |
| J12.82 | Pneumonia due to coronavirus disease 2019 |
| U07.1 | COVID-19 |
| U09.9 | Post-COVID-19 condition, unspecified |
A note on the COVID codes: D57.00–D57.819 are your qualifying diagnosis codes for Adakveo billing. The COVID codes (U07.1, U09.9, J12.82) appear in the policy's code database but are not covered indications. Talk to your compliance officer if you're billing Adakveo for any patient where a COVID diagnosis is the primary clinical driver — that's a coverage policy mismatch that will surface on audit.
Get the Full Picture for CPT 96365
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.